Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Insulin Glargine Dosing Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for Surgical Procedure~* Self Management of Diabetes~* Currently on Evening Insulin Glargine prescribed by Primary Care Physician~* Age 18 or over~* Able to Communicate Clearly over the Phone~* Pre-screened by Anesthesia Department \> 48 hours prior to Surgery~Exclusion Criteria:~* On Glucocorticoid Medication~* On Insulin Glargine Dual Dosing or Sliding Scale Regimen~* History of Hypoglycemia Unawareness~* Pregnancy or Lactating Female~* On Insulin Glargine for \< 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients in Group 1 will administer 80% of their usual insulin glargine dose.
- 2 (Type: ACTIVE_COMPARATOR): Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
- 3 (Type: EXPERIMENTAL): Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.

Based on this trial design, predict the completion outcome and termination type (if applicable).